Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by MyKnighton Feb 11, 2020 3:49pm

110 Views

Post# 30676341

RE:RE:RE:RE:This company

Reverse split isnot an issue, it's out.

You should care about the amount of share the MC is the indicator.

For example
TBP.v as a MC of 90.46 Millions (11/feb/2020)
Kly.v as a MC of 20.62 Millions (11/feb/2020)

Which one will be at 1 Billions of MC before the other one?

My Money is on Kaly therapeutic.

And soooooon,,,,

RE:RE:RE:This company
One major problem for kaly is reverse split, I know they said not going to do that but I don't believe them... that's huge and TBP only has 200mil shares as apposed to 600mil big difference in end price...

Bullboard Posts

Payfare stock nosedives after losing biggest client, DoorDash